Immunogenicity and reactogenicity of a reduced antigen content diphteria-tetanus-acellular pertussis vaccine (dTpa) in 10 to 11 years old children and in adults;Inmunogenicidad y reactogenicidad de una vacuna de difteria, tétanos, pertussis acelular de contenido antigénico reducido (dTpa) en niños de 10 a 11 años de edad y en adultos

Revista Medica de Chile

Volumn 130, Issue 5, 2002, Pages 502-510

  Abarca V , Katia ^a,b   Valdivieso R , Francisca ^a   Potin S , Marcela ^a   Ibáñez W , Isabel ^a   Vial C , Pablo ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b NONE   (Chile)

Author keywords

Diphteria Tetanus Pertussis vaccine, vaccines, attenuated; Vaccines, combined

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ;

ADULT; ARTICLE; BLOOD; CHILD; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED;

ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHILD; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTININS; HUMANS; MALE; MIDDLE AGED; VIRULENCE FACTORS, BORDETELLA;

EID: 0347939350     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. rd Ed 1999; 293-344.
2. SÁNCHEZ I, REPETTO G, SAENGER A. Epidemiología de la tos ferina en Chile (1950-1990). El adulto ¿nuevo reservorio de infección? Rev Méd Chile 1994; 122: 339-45.
3. CDC. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. Recommendations of the ACIP. Morbidity and Mortality Weekly Report 1997; 46; No RR-7.
4. BASS JW, WITTLER RR. Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994; 13: 343-5.
5. DE MELKER H, SCHELLENKENS JEP, NEPPELENBROEK SE, MOOI FR, RUMKE HC, CONYN-VAN SPAENDONCK MAE. Reemergence of pertussis in the highly vaccinated population of the Netherlands: Observations on surveillance data. Emerging Infectious Diseases 2000; 6: 348-57.
6. HE Q, VILJANEN MK, NIKKARI S, LYYTIKAINEN R, MERTSOLA J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 1994; 170: 873-7.
7. MINSAL-Chile. La Tos Ferina en Chile. Boletín de Vigilancia Epidemiológica "El Vigía" 1999; 6: 2-4.
8. LINNEMANN CC, NASENBENY J. Pertussis in the adult. Ann Rev Med 1977; 28: 179-85.
9. AOYAMA T, TAKEUCHI Y, GOTO A, IWAI H, MURASE Y, IWATA T. Pertussis in adults. Am J Dis Child 1992; 146: 163-6.
10. JENKINSON D. Duration of effectiveness of pertussis vaccine: evidence from a 10 years community study. Br Med 1988; 296: 612-4.
11. VON KÖNIG WIRSING CH, POSTELS-MULTANI S, BOCK HL, SCHMITT HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995; 346: 1326-9.
12. AOYAMA T, HARASHIMA M, NISHIMURA K, SAITO Y. Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Pediatrica Japonica 1995; 37: 321-4.
13. DEEN JL, MINK CM, CHERRY JD, CHRISTENSON P, PINEDA E, LEWIS K ET AL. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995; 21: 1211-9.
14. MERTSOLA J, RUUSKANEN O, EEROLA E, VILJANN MK. Intrafamiliar spread of pertussis. J Ped 1983; 103: 359-63.
15. NELSON JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Dis Child 1978; 132: 371-3.
16. BLACK S. Epidemiology of pertussis. Pediatr Infect Dis J 1997; 16: S 85-9.
17. Centers for Disease Control. Pertussis Surveillance: United States, 1986-88. MMWR 1990; 39: 57-66.
18. TROLLFORS B, RABO E. Whooping cough in adults. British Med Journal 1981; 283: 198-9.
19. POSTELS-MULTANI S, SCHMITT HJ, VON KONIG W, BOCK HL, BOGAERTS H. Symptoms and complications of pertussis in adults. Infection 1995; 23: 139-42.
20. MINK CM, SIROTA NM. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch Ped Adolesc Med 1994; 148: 153-7.
21. MINK CM, CHERRY JD, CHRISTENSON, LEWIS K, PINEDA E, SHLIAN D ET AL. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: 464-71.
22. SCHMITT-GROTHE S, CHERRY JD, HEININGER U, UBERALL M, PINEDA E, STEHR K. Pertussis in german adults. Clin Infect Dis 1995; 2184: 860-6.
23. KEITEL WA, EDWARDS KM. Pertussis in adolescents and adults: time to reimmunize? Semin Resp Infect 1995; 10: 51-7.
24. IMMUNIZATION PRACTICE ADVISORY COMMITTEE (ACIP). Diphteria, tetanus and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practice Advisory Committee (ACIP) MMWR 1991; 40 (RR10): 1-28.
25. GRECO D, SALMASO S, MASTRANTONIO P, GIULIANO M, TOZZI AE, ANEMONA A ET AL. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334: 341-8.
26. GUSTAFSSON L, HALLANDER HO, OLIN P, REIZENSTEIN E, STORSAETER J. A controlled trial of a two-component acellular, a five component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349-55.
27. PICHICHERO ME. Acellular pertussis vaccines: Towards an improved safety profile. Drug Safety 1996; 15: 311-24.
28. OLIN P, RASMUSSEN F, GUSTAFSSON L, HALLANDER HO, HEIJBEL H. Randomized controlled trial of two component, three component and five component acellular pertussis vaccines compared with whole cell pertussis vaccine. Lancet 1997; 350: 1569-77.
29. SIMONDON F, YAM A, GAGNEPAIN JY ET AL. Comparative safety and immunigenicity of an acellular versus whole cell pertussis component of diphteria-tetanus-pertussis vaccines in Senegalese infants. Eur J Clin Microbiol Infect Dis 1996; 15: 927-32.
30. SCHMITT HJ, VÖN KONING W, NEISS A, BOGAERTS H, BOCK H, SCHULTE-WISSERMAN H ET AL. Efficacy of acellular pertussis vaccine in infants after household exposure. JAMA 1996; 275: 37-41.
31. HALPERIN S, SMITH B, RUSSELL M, SCHEIFELE D, MILLS E, HASSELBACK P ET AL. Adult formulation of five component acellular pertussis vaccine combined with diphteria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J 2000; 19: 276-83.
32. VAN DER WIELEN M, VAN DAMME P, JOOSSENS E, FRANCOIS G, MEURICE F, RAMAHLO A. A randomized controlled trial with a diphteria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000; 18: 2075-82.
33. TURNBULL FM, HEATH TC, JAJALUDIN BB, BURGESS MA, RAMALHO AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diptheria-tetanus vaccine (Td) in adults. Vaccine 2001; 19: 628-36.
34. CHERRY JD, GORNBEIN J, HEININGER U, STEHR K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901-6.
35. STORSAETER J, HALLANDER H, GUSTAVSSON L, OLIN P. Levels of anti-pertussis antibodies over time related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907-16.
36. DAGAN R, IGBARIA K, PIGLANSKY L, VAN BRUSTEGHEM F, MELOT V, KAUFHOLD A. Reactogenicity and immunogenicity of reduced antigen content diphteria, tetanus and acellular pertussis vaccines as a booster in 4-7 years old children primed with diftheria, tetanus and whole cell before 2 years of age. Vaccine 1999; 17: 2620-27
37. MIDEPLAN. Encuesta Casen, 2000.